Catalent, Inc. (NYSE:CTLT) Stock Holdings Trimmed by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. cut its stake in shares of Catalent, Inc. (NYSE:CTLT) by 3.6% in the 4th quarter, Holdings Channel reports. The firm owned 73,746 shares of the company’s stock after selling 2,725 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Catalent were worth $3,358,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Cetera Advisor Networks LLC lifted its position in Catalent by 7.1% in the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock worth $217,000 after purchasing an additional 130 shares during the period. Mackay Shields LLC raised its stake in Catalent by 0.6% during the 1st quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock valued at $2,856,000 after purchasing an additional 149 shares during the period. Wetherby Asset Management Inc. increased its stake in shares of Catalent by 5.1% in the first quarter. Wetherby Asset Management Inc. now owns 5,023 shares of the company’s stock worth $557,000 after acquiring an additional 243 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its stake in shares of Catalent by 1.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 21,164 shares of the company’s stock worth $953,000 after acquiring an additional 252 shares during the last quarter. Finally, Covestor Ltd increased its stake in shares of Catalent by 84.9% in the first quarter. Covestor Ltd now owns 562 shares of the company’s stock worth $62,000 after acquiring an additional 258 shares during the last quarter.

Catalent Stock Performance

CTLT stock opened at $56.92 on Friday. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The company has a 50 day moving average price of $56.95 and a 200 day moving average price of $47.80. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $66.41. The stock has a market capitalization of $10.29 billion, a PE ratio of -8.37, a price-to-earnings-growth ratio of 6.11 and a beta of 1.20.

Catalent (NYSE:CTLT) last released its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm posted $0.62 EPS. Catalent’s revenue was down 10.2% on a year-over-year basis. Analysts forecast that Catalent, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CTLT shares. UBS Group reiterated a “neutral” rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. Stephens reissued an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Barclays lifted their target price on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Finally, StockNews.com started coverage on shares of Catalent in a research note on Thursday. They set a “sell” rating for the company. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $52.46.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.